Pharmaceutical

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Uncertainty over drug pipeline sends Lilly shares down

October 21, 2009
J.K. Wall
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
More

Lilly reports $942 million profit in third quarter

October 21, 2009
J.K. Wall
Excluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008, to $5.56 billion.
More

Medco plans to compare Plavix, Effient in study

October 20, 2009
 IBJ Staff and Associated Press
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
More

Endocyte receives $26M infusion from investors

October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company continue developing cancer-fighting drugs.
More

Lilly to pay Idaho $13M in drug settlement

October 14, 2009
 IBJ Staff and Associated Press
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of anti-psychotic drug Zyprexa.
More

Lilly to sell Lafayette plant to German firm

October 14, 2009
J.K. Wall
Nearly 700 workers will be offered severance, new jobs
More

Lilly settles Zyprexa suit with S. Carolina

October 7, 2009
 IBJ Staff
Eli Lilly and Co. has agreed to settle the State of South Carolina's lawsuit that claimed Lilly improperly marketed the antipsychotic drug Zyprexa, according to Bloomberg News.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More

Judge upholds Lilly's Evista patent

September 24, 2009
J.K. Wall
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced late yesterday.
More

Lilly agrees to settle more state Zyprexa suits

September 22, 2009
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
More

UPDATE: Pipeline challenges force Lilly restructuring moves

September 14, 2009
J.K. Wall
Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
More

Lilly reorganization to cut 5,500 positions over 2 years

September 14, 2009
J.K. Wall
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central Indiana. But with 13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More

Local health care industry tries to capitalize on migraine headaches

September 12, 2009
J.K. Wall
Migraines cost American employers $20 billion a year in decreased worker productivity. Such a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
More

Lilly paid doctors to prescribe Zyprexa, notes say

September 8, 2009
 IBJ Staff
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers' program in exchange for prescribing the antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
More

AIT Laboratories leaps up Inc.'s list

August 24, 2009
 IBJ Staff
The Indianapolis-based forensics, clinical and pharmaceutical testing firm now ranks 598, up from 1,466 a year ago. The list is based on percentage of revenue growth.
More

Lilly drops osteoporosis pipeline drug

August 18, 2009
J.K. Wall
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating the company’s attempts to find revenue before losing patent protection on its bestseller.
More

Lilly pays $224,000 to area doctors

August 17, 2009
 IBJ Staff
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first quarter.
More

Lilly's Effient launch just one of its many challengesRestricted Content

August 3, 2009
Greg Andrews
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
More

Arcadia hopes health care reform means more revenueRestricted Content

August 3, 2009
J.K. Wall
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company's fast-growing DailyMed service.
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

Potential obesity breakthrough boosts Marcadia

July 20, 2009
J.K. Wall
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
More

Drug industry funds Democrat-led panel on health care reformRestricted Content

July 20, 2009
J.K. Wall
The pharmaceutical industry—which for two decades has given twice as much in campaign donations to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis to argue its position on health care reform.
More

Professors go online to revolutionize drug discoveryRestricted Content

July 20, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
More

BREAKING: FDA approves Lilly blood-thinner prasugrel

July 10, 2009
J.K. Wall
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner, according to Bloomberg News.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT